van Rhee Frits, Greenway Amy, Stone Katie
UAMS Myeloma Institute, University of Arkansas for Medical Sciences, 4301 West Markham, #816, Little Rock, AR 72205, USA.
UAMS Myeloma Institute, University of Arkansas for Medical Sciences, 4301 West Markham, #816, Little Rock, AR 72205, USA.
Hematol Oncol Clin North Am. 2018 Feb;32(1):89-106. doi: 10.1016/j.hoc.2017.09.008.
Important progress has been made in the treatment of idiopathic multicentric Castleman disease (iMCD) with the introduction of interleukin-6 targeting monoclonal antibodies. This article describes the clinical results obtained with different treatment modalities and uses this evidence to provide treatment guidelines for the practicing clinician. Much is still to be learned about the pathophysiology of iMCD and further research is urgently needed to develop novel and curative treatment approaches for all patients.
随着白细胞介素-6靶向单克隆抗体的引入，特发性多中心Castleman病（iMCD）的治疗取得了重要进展。本文描述了不同治疗方式所取得的临床结果，并利用这些证据为临床医生提供治疗指南。关于iMCD的病理生理学仍有许多有待了解之处，迫切需要进一步研究以开发针对所有患者的新型治愈性治疗方法。
